Cumberland Pharmaceuticals (NASDAQ:CPIX) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research note issued to investors on Monday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Trading Up 0.3 %

Shares of CPIX opened at $1.69 on Monday. The company has a current ratio of 1.62, a quick ratio of 1.21 and a debt-to-equity ratio of 0.36. The firm’s 50-day moving average is $1.56 and its two-hundred day moving average is $1.81. Cumberland Pharmaceuticals has a twelve month low of $1.43 and a twelve month high of $2.91. The firm has a market capitalization of $24.29 million, a P/E ratio of -13.00 and a beta of 0.32.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $0.15 earnings per share for the quarter. Cumberland Pharmaceuticals had a negative net margin of 4.39% and a positive return on equity of 11.44%. The company had revenue of $10.89 million for the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Cumberland Pharmaceuticals in the second quarter valued at approximately $133,000. Millennium Management LLC acquired a new position in shares of Cumberland Pharmaceuticals in the fourth quarter worth $46,000. True Capital Management purchased a new stake in shares of Cumberland Pharmaceuticals in the fourth quarter valued at $27,000. Renaissance Technologies LLC boosted its stake in shares of Cumberland Pharmaceuticals by 6.3% during the first quarter. Renaissance Technologies LLC now owns 644,763 shares of the specialty pharmaceutical company’s stock valued at $1,818,000 after acquiring an additional 38,100 shares during the last quarter. Finally, Acadian Asset Management LLC increased its position in Cumberland Pharmaceuticals by 27.8% during the 1st quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock worth $529,000 after purchasing an additional 40,949 shares in the last quarter. 16.95% of the stock is currently owned by institutional investors and hedge funds.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals, Inc is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex.